Editas Medicine reported its financial results for the fourth quarter and full year 2024 on March 5, 2025. The Company's cash, cash equivalents, and marketable securities were $269.9 million as of December 31, 2024.
The Company expects its existing cash, cash equivalents, and marketable securities, along with retained portions of Vertex Pharmaceuticals payments, to fund operating expenses and capital expenditures into the second quarter of 2027. Total estimated expenses related to ending reni-cel development and employee exit costs are approximately $45.0 million to $55.0 million.
Editas Medicine remains on track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025. The net loss for the fourth quarter of 2024 was $45.4 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.